These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21992561)

  • 1. Herceptin-directed nanoparticles activated by an alternating magnetic field selectively kill HER-2 positive human breast cells in vitro via hyperthermia.
    Zhang J; Dewilde AH; Chinn P; Foreman A; Barry S; Kanne D; Braunhut SJ
    Int J Hyperthermia; 2011; 27(7):682-97. PubMed ID: 21992561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.
    Kang SH; Kang KW; Kim KH; Kwon B; Kim SK; Lee HY; Kong SY; Lee ES; Jang SG; Yoo BC
    BMC Cancer; 2008 Oct; 8():286. PubMed ID: 18834540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers.
    Mi Y; Liu X; Zhao J; Ding J; Feng SS
    Biomaterials; 2012 Oct; 33(30):7519-29. PubMed ID: 22809649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Killing effect of 131I-Herceptin on breast cancer cell lines in vitro].
    Lin J; Luo RC; Li AM; Zhang JY; Lü CW; Yan X
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):663-6. PubMed ID: 15958303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene].
    Guo MG; Jiang MH; Yang Q; Li YM; Cui ZF; Li LF; Wu MC; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1147-51. PubMed ID: 15387973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors.
    Talukder AH; Bagheri-Yarmand R; Williams RR; Ragoussis J; Kumar R; Raz A
    Clin Cancer Res; 2002 Oct; 8(10):3285-9. PubMed ID: 12374700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
    McKenzie T; Liu Y; Fanale M; Swisher SG; Chada S; Hunt KK
    Surgery; 2004 Aug; 136(2):437-42. PubMed ID: 15300212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of HER-2/neu in uterine serous papillary cancer.
    Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
    Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate.
    Li Y; Cozzi PJ; Qu CF; Zhang DY; Abbas Rizvi SM; Raja C; Allen BJ
    Cancer Lett; 2004 Mar; 205(2):161-71. PubMed ID: 15036648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells.
    Bocangel D; Zheng M; Mhashilkar A; Liu Y; Ramesh R; Hunt KK; Chada S
    Cancer Gene Ther; 2006 Oct; 13(10):958-68. PubMed ID: 16783343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
    Fan YX; Luo RC; Fang YX; Yan X; Lu CW
    Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Killing effect of Photofrin-Herceptin immunoconjugate on tumor cell lines in vitro].
    Qian XY; Luo RC; Li LB; Liao WJ; Luo YL
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Aug; 25(8):975-8. PubMed ID: 16109553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery.
    Kossatz S; Grandke J; Couleaud P; Latorre A; Aires A; Crosbie-Staunton K; Ludwig R; Dähring H; Ettelt V; Lazaro-Carrillo A; Calero M; Sader M; Courty J; Volkov Y; Prina-Mello A; Villanueva A; Somoza Á; Cortajarena AL; Miranda R; Hilger I
    Breast Cancer Res; 2015 May; 17(1):66. PubMed ID: 25968050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroma cells: a novel target of herceptin activity.
    Corsini C; Mancuso P; Paul S; Burlini A; Martinelli G; Pruneri G; Bertolini F
    Clin Cancer Res; 2003 May; 9(5):1820-5. PubMed ID: 12738740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Herceptin therapy in breast cancer: new indication?].
    Lebeau A
    Verh Dtsch Ges Pathol; 2006; 90():99-106. PubMed ID: 17867585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herceptin-platinum(II) binding complexes: novel cancer-cell-specific agents.
    Gao J; Liu YG; Liu R; Zingaro RA
    ChemMedChem; 2008 Jun; 3(6):954-62. PubMed ID: 18366039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple Therapy of HER2
    Zolata H; Afarideh H; Davani FA
    Cancer Biother Radiopharm; 2016 Nov; 31(9):324-329. PubMed ID: 27831759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.